06 / About Clinaptis

Independent
by design.

Clinaptis is an independent biopharma research platform built to examine the gap between reported evidence, market expectations and investment outcomes.

Research philosophy

The conclusion matters.
The variables matter more.

  1. 01Reconstruct the evidence

    Normalize trials, endpoints and populations before comparing the headline.

  2. 02Make expectations explicit

    Ask what the valuation and prevailing narrative already appear to assume.

  3. 03Define what changes the view

    Separate conviction from certainty through auditable assumptions and sensitivities.

Founder & editor

Bikram K. Singh, MBBS

Bikram K. Singh, MBBS, is the founder and editor of Clinaptis. He brings together a medical background with buy-side hedge fund and sell-side equity research experience. His work focuses on clinical-trial interpretation, market expectations and valuation across public biopharma—particularly where a headline result obscures the variables that determine the investment outcome.

Clinaptis grew from independent published research and a conviction that rigorous judgment becomes more useful when its evidence, assumptions and failure conditions are visible.

Contact

Research enquiries,
ideas and collaboration.